Eli Lilly and Company (NYSE:LLY) Shares Acquired by Cabot Wealth Management Inc.

Cabot Wealth Management Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 6,355 shares of the company’s stock after buying an additional 107 shares during the period. Cabot Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $4,906,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. MONECO Advisors LLC lifted its stake in shares of Eli Lilly and Company by 26.7% during the 4th quarter. MONECO Advisors LLC now owns 4,100 shares of the company’s stock worth $3,165,000 after purchasing an additional 863 shares during the period. DORCHESTER WEALTH MANAGEMENT Co purchased a new position in Eli Lilly and Company during the fourth quarter worth about $227,000. Lansing Street Advisors boosted its stake in Eli Lilly and Company by 102.5% in the 4th quarter. Lansing Street Advisors now owns 1,312 shares of the company’s stock worth $1,013,000 after buying an additional 664 shares during the last quarter. Howard Capital Management Inc. grew its holdings in Eli Lilly and Company by 5.5% in the 4th quarter. Howard Capital Management Inc. now owns 7,530 shares of the company’s stock valued at $5,813,000 after buying an additional 392 shares during the period. Finally, Wealthspire Advisors LLC grew its holdings in Eli Lilly and Company by 23.8% in the 4th quarter. Wealthspire Advisors LLC now owns 8,709 shares of the company’s stock valued at $6,724,000 after buying an additional 1,672 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $874.12 on Friday. The firm has a fifty day simple moving average of $801.33 and a 200-day simple moving average of $847.13. The company has a market capitalization of $828.82 billion, a PE ratio of 74.65, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has approved a stock buyback plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s payout ratio is currently 51.24%.

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Wolfe Research started coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target on the stock. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Wells Fargo & Company reduced their target price on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Finally, Bank of America restated a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,000.28.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.